Synthetic Dyes in Pharmaceuticals: A Comprehensive Review

Abstract

Introduction: Synthetic color additives are widely used as excipients in prescription and over-the-counter pharmaceuticals to aid product identification, branding, and patient adherence. Warm colors like red, orange, and yellow are perceived as stimulating, pink as mild, gentle, or comforting, while cool colors like blue and green are associated with calmness or sedation, potentially influencing patient expectations. Despite regulatory assumptions of safety, case reports and small clinical series describe hypersensitivity reactions to dye-containing medicinal products, and perioperative anaphylaxis has been documented with injectable vital dyes used for sentinel lymph node mapping.

Methods: We searched the biomedical and regulatory literature for studies and reports describing synthetic dyes in medicinal products (including oral, parenteral, and topical formulations, as well as diagnostic dyes). We included human clinical and epidemiologic studies, toxicology evaluations, and regulatory assessments in which dyes were used as excipients or as active diagnostic agents. Food-only exposure studies were excluded from the main analysis and considered only for mechanistic context.

Results: Most synthetic dyes used in pharmaceuticals are azo or triarylmethane compounds derived from petroleum products. These include FD&C Yellow No. 5 (tartrazine), FD&C Yellow No. 6 (sunset yellow FCF), FD&C Red No. 40 (Allura Red AC), and triarylmethane dyes such as patent blue V and isosulfan blue. Clinical evidence in medicinal products is dominated by (1) perioperative anaphylaxis to blue mapping dyes during breast and melanoma surgery; (2) immediate hypersensitivity reactions to tartrazine and other azo dyes used as tablet and solution colorants; and (3) small series in which switching from colored to dye-free formulations results in symptom resolution. Population-based incidence data are sparse, but available series suggest that severe reactions to blue mapping dyes occur in approximately 0.1-1% of exposed patients, whereas clinically significant reactions to oral excipient dyes appear rare and concentrated in patients with underlying atopy, chronic urticaria, or multiple drug "allergies." Toxicology and regulatory assessments identify additional concerns, including thyroid tumors in preclinical models with erythrosine and genotoxicity or tumor-promoting signals for certain azo dyes at high doses.

Conclusions: The human data support the conclusion that synthetic dyes in pharmaceuticals are not biologically inert. Taken together, the evidence supports a precautionary, risk-stratified approach in which synthetic dyes are recognized as unnecessary excipients with no therapeutic benefit and real-if infrequent-potential for harm. Dye additives may preclude use of important medications for patients and thus are a significant barrier to treatment for those with intolerances. Accordingly, supply-chain preference should be given to dye-free or non-toxic alternative formulations whenever feasible.